Representing injured workers in Pennsylvania, we see many severe injuries. One condition which certainly belongs in this category is Reflex Sympathetic Dystrophy (RSD), otherwise known as Complex Regional Pain Syndrome (CRPS). This debilitating condition has been discussed on our blog in the past.
Since a hallmark of RSD/CRPS is incapacitating pain, much of the challenge in treating patients with the condition is providing some level of relief. A tool which may be coming to the arsenal of pain management physicians in the future is Neridronic Acid. Clinical trials of this medication are promising enough to have led the U.S. Food and Drug Administration (FDA) to label Neridronic Acid with the Breakthrough Therapy designation, as noted by the U.S. National Institute of Health (NIH). These clinical trials appear to have shown a significant reduction in pain and symptoms of CRPS with the Neridronic Acid treatment, as reported by Pain News Network.
We will be keeping an eye on this, and other, avenues that the medical community pursues to care for injured workers with this serious condition.